Effects of TNX-832 (Sunol cH36) in Subjects With Acute Lung Injury/Acute Respiratory Distress Syndrome

This study has been completed.
Sponsor:
Collaborators:
Genentech
Tanox
Information provided by (Responsible Party):
Altor Bioscience Corporation
ClinicalTrials.gov Identifier:
NCT01438853
First received: September 20, 2011
Last updated: September 21, 2011
Last verified: September 2011

September 20, 2011
September 21, 2011
December 2004
July 2006   (final data collection date for primary outcome measure)
  • Safety assessed by number of adverse events, and changes in vital signs, ECGs, laboratory, coagulation and pulmonary function parameters. [ Time Frame: Throughout the 4 weeks following treatment ] [ Designated as safety issue: Yes ]
    To evaluate the safety of escalating dose levels of TNX-832 in subjects with suspected or proven bacteria-induced ALI/ARDS. Safety was assessed by number of treatment emergent adverse events, and changes in vital signs, ECGs, laboratory, coagulation and pulmonary function parameters from baseline. Immunogenicity (serum anti-TNX-832 antibody response) was evalutated.
  • Composite of pharmacokinetics [ Time Frame: predose; 15 and 30 min; 1, 4, 6, 12 and 24 hrs; 2, 3, 4, 5, 6, and 7 days, 2, 3, 4 weeks ] [ Designated as safety issue: No ]
    To evaluate the pharmacokinetics of escalating dose levels of TNX-832 in subjects with suspected or proven bacteria-induced ALI/ARDS. Pharmacokinetic parameters assessed are terminal half life, maximum serum concentration, volume of distribution, total body clearance, area under the drug concentration versus time curve extrapolated to infinity.
Same as current
Complete list of historical versions of study NCT01438853 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Effects of TNX-832 (Sunol cH36) in Subjects With Acute Lung Injury/Acute Respiratory Distress Syndrome
The Safety, Pharmacokinetics, and Pharmacodynamic Effects of TNX-832 (Sunol cH36) in Subjects With Acute Lung Injury/Acute Respiratory Distress Syndrome

This Phase I/IIa, multi-center, randomized, placebo-controlled, single-blinded dose-escalation study evaluated TNX-832 (also referred to as ALT-836 and Sunol cH36) in subjects with suspected or proven bacteria-induced ALI/ARDS. Up to five cohorts of at least six subjects each were originally planned. Subjects were to be randomized in a 5:1 ratio to receive TNX-832 or placebo,respectively, administered as a single bolus infusion over 15 minutes. Three cohorts of subjects were enrolled to the study and safety and pharmacokinetics of the study treatment were evaluated.

Tissue factor (TF) is a transmembrane glycoprotein that acts as the principal initiator of the extrinsic coagulation pathway. TF is a key mediator between the immune system and coagulation and is the principal activator of coagulation. The TF-FVIIa complex activates FX and FIX, resulting in the cleavage of prothrombin to thrombin. Normally, localized activation of the coagulation cascade associated with inflammatory responses plays a role in controlling the spread of infectious agents; however, aberrant TF expression often leads to serious thrombotic disorders. TF-dependent thrombosis has been associated with many diseases including septic shock, coronary artery disease (CAD), cancer, and many inflammatory and autoimmune disorders such as lupus, rheumatoid arthritis, psoriasis, and inflammatory bowel disease.

Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are forms of acute respiratory failure characterized by diffuse pulmonary infiltrates, pulmonary hypertension, refractory hypoxemia, loss of pulmonary compliance and normal hydrostatic pressures. ALI and ARDS commonly occur in patients with acute catastrophic events such as sepsis, trauma and severe pulmonary infections. The incidence of ALI and ARDS is extremely high in patients with sepsis. By blocking the initiating events of extrinsic coagulation activation, their effects on pro-inflammatory events in the lungs and disordered fibrin deposition may be corrected and the evolution of severe structural and functional injury may be averted during ALI/ARDS. TNX-832 (formerly known as Sunol-cH36), directed against human TF, which can block the pathological complications of TF-dependent thrombus formation. The blockage by TNX-832 of initiating events in the extrinsic coagulation pathway may attenuate the effects on pro-inflammatory events in ALI/ARDS patients, thereby averting or decreasing disordered fibrin deposition and averting the evolution of severe structural and functional injury.

Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Treatment
  • Sepsis
  • Acute Lung Injury
  • Acute Respiratory Distress Syndrome
  • Biological: TNX-832
    Single intravenous dose of TNX-832 at 0.06, 0.08 or 0.10 mg/kg
    Other Names:
    • ALT-836
    • Sunol cH36
  • Drug: Placebo
    Single intravenous dose of saline control
  • Experimental: TNX-832
    Anti-tissue factor antibody
    Intervention: Biological: TNX-832
  • Placebo Comparator: Drug Placebo
    Placebo control
    Intervention: Drug: Placebo
Morris PE, Steingrub JS, Huang BY, Tang S, Liu PM, Rhode PR, Wong HC. A phase I study evaluating the pharmacokinetics, safety and tolerability of an antibody-based tissue factor antagonist in subjects with acute lung injury or acute respiratory distress syndrome. BMC Pulm Med. 2012 Feb 16;12:5. doi: 10.1186/1471-2466-12-5.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
18
February 2008
July 2006   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. ≥ 18 years
  2. Suspected or proven bacterial infection
  3. Receiving positive pressure ventilation through an endotracheal tube
  4. Have ALI/ARDS, defined as having all of the following:

    • bilateral infiltrates consistent with pulmonary edema
    • Hypoxemia
    • no clinical evidence of left atrial hypertension
  5. Provide signed informed consent

Exclusion Criteria:

  1. Mechanically or chemically-induced ALI/ARDS (including burns, trauma, and near drowning)
  2. End-stage lung disease
  3. Decompensated congestive heart failure
  4. Authorization to withdraw life support
  5. Hemoglobin persistently <8.0 g/dL
  6. Subjects who have any one of the following:

    • platelet count <50,000/mm^3
    • prolonged prothrombin time (PT)
    • prolonged activated partial thromboplastin time (aPTT)
    • having significant potential for disseminated intravascular coagulation (DIC)
  7. Subjects who have two or more of the following:

    • prolonged aPTT
    • fibrinogen level below the lower limit of normal
    • presence of petechiae, ecchymoses, or other evidence of coagulopathy
  8. Subjects who have a history of one or more of the following:

    • hematuria (microscopic or gross)
    • urinary tract neoplasia
    • nephrolithiasis
    • glomerulonephritis
    • active urinary tract infection (UTI)
  9. Bleeding disorders within the past 6 weeks or vasculitis with diffused alveolar hemorrhage
  10. Diagnosis of bleeding peptic ulcer disease within the previous 2 months
  11. Congenital bleeding diatheses such as hemophilia
  12. Treatment with anti-platelet, anti-coagulant agents, or non-steroidal anti-inflammatory drugs (NSAIDs)within 72 hours following infusion of study drug

    • Therapeutic heparin:

      • Unfractionated heparin within eight hours prior to study drug infusion
      • Low molecular weight heparins within the 12 hours prior to study drug infusion
    • Prophylactic heparin:

      • Unfractionated heparin >15,000 units/day
      • Low molecular weight heparins
    • Warfarin if used within 7 days prior to study drug infusion
    • Thrombolytic treatment within 3 days prior to study drug infusion
    • 8Glycoprotein IIb/IIIa antagonists within 7 days prior to study drug infusion
    • Aspirin or any aspirin containing compound within 3 days prior to study drug infusion
    • APC infusion within 72 hours prior to study drug infusion
  13. Major trauma or trauma subjects at an increased risk of bleeding
  14. History of severe head trauma that required hospitalization, intracranial surgery, or stroke or any history of intracerebral arteriovenous malformation, cerebral aneurysm, or central nervous system mass lesion with an epidural catheter or who anticipate receiving an epidural catheter during study drug infusion
  15. Major surgery within the previous 3 days, any postoperative subject with evidence of active bleeding, or any subject with planned or anticipated surgery within 72 hours after study drug infusion. History of abnormal bleeding during surgical procedures
  16. Chronic renal failure, defined as a calculated glomerular filtration rate (GFR) ≤20 mL/min
  17. Subjects with baseline aspartate transaminase (AST) or alanine transaminase (ALT) level >5 times the upper limit of normal. Subjects with known esophageal varices, chronic jaundice, biopsy proven cirrhosis, or chronic ascites
  18. History of organ transplant (including bone marrow)
  19. Subjects with malignancy having a life expectancy <6 months
  20. Known human immunodeficiency virus (HIV) positive with CD4+ T Cell count <200/uL
  21. Women who are pregnant or nursing
  22. Participation in another clinical research study within 30 days before administration of study drug, with the exception of participation in studies involving noninvasive monitoring medical devices
  23. Any prior treatment with a murine or chimeric antibody
  24. Subjects who are moribund and where death is perceived to be imminent (within 72 hours after screening)
  25. Subjects who have persistent hypotension not responding to fluid or vasopressor administration; subjects who require more than two vasopressors 26. Any medical condition which in the opinion of the investigator would interfere with optimal participation in the study or that would produce a significant risk to a subject
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States,   Canada
 
NCT01438853
TNX-832.201
Yes
Altor Bioscience Corporation
Altor Bioscience Corporation
  • Genentech
  • Tanox
Study Director: Hing Wong, PhD Altor Bioscience
Altor Bioscience Corporation
September 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP